Skip to content

Study · In vitro (cells) · 2014

3 results

Kisspeptin-10 inhibits stromal-derived factor 1-induced invasion of human endometrial cancer cells.

Schmidt E, Haase M, Ziegler E, Emons G, Gründker C

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society1 Feb 2014Cited by 19 (Europe PMC)

PMID24407584 (opens in a new tab)DOI10.1097/igc.0000000000000050 (opens in a new tab)PepBankPUB-24407584
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In human endometrial cancer cells, kisspeptin‑10 reduced invasion through a reconstituted basement membrane, with a significant effect at 10(-13) to 10(-11) mol/L.

    In plain wordsIn cancer cells in the lab, kisspeptin‑10 reduced the ability of human endometrial cancer cells to invade.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseEndometrial cancer cell invasion through basement membrane
    Study

    humann: not reported in source

    Human endometrial cancer cells (coculture with MG63 osteoblast-like cells)
    Outcome group
    Tumor growth · Cancer
    Studied dose
    10(-13) to 10(-11) mol/LAs given in this study (human).

    Source sentences

    Summary
    Treatment with KP-10 reduced the ability to invade a reconstituted basement membrane and to migrate in response to the cellular stimulus.
    2 context sentences
    Summary · context
    This effect was significant in a dose window of 10(-13) to 10(-11) mol/L.
    Summary · context
    Furthermore, the effects of KP-10 treatment on MG63 coculture-driven and SDF-1-induced invasion were analyzed.
  2. 02LabIn vitro (cells)Efficacy outcome

    In human endometrial cancer cells, kisspeptin‑10 reduced migration in response to the cellular stimulus, with a significant effect at 10(-13) to 10(-11) mol/L.

    In plain wordsIn cancer cells in the lab, kisspeptin‑10 reduced the movement of human endometrial cancer cells.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseEndometrial cancer cell migration in response to cellular stimulus
    Study

    humann: not reported in source

    Human endometrial cancer cells (coculture with MG63 osteoblast-like cells)
    Outcome group
    Tumor growth · Cancer
    Studied dose
    10(-13) to 10(-11) mol/LAs given in this study (human).

    Source sentences

    Summary
    Treatment with KP-10 reduced the ability to invade a reconstituted basement membrane and to migrate in response to the cellular stimulus.
    2 context sentences
    Summary · context
    This effect was significant in a dose window of 10(-13) to 10(-11) mol/L.
    Summary · context
    Furthermore, the effects of KP-10 treatment on MG63 coculture-driven and SDF-1-induced invasion were analyzed.
  3. 03LabIn vitro (cells)Efficacy outcome

    In human endometrial cancer cells, kisspeptin‑10 significantly reduced the increase in invasion that SDF-1 caused.

    In plain wordsIn cancer cells in the lab, kisspeptin‑10 reduced the extra invasion that SDF-1 caused in human endometrial cancer cells.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseSDF-1-induced endometrial cancer cell invasion
    Study

    humann: not reported in source

    Human endometrial cancer cells (coculture with MG63 osteoblast-like cells)
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The SDF-1-induced increase of endometrial cancer cell invasion was significantly reduced after treatment with KP-10.
    1 context sentence
    Summary · context
    Furthermore, the effects of KP-10 treatment on MG63 coculture-driven and SDF-1-induced invasion were analyzed.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.